AbbVie licenses antibody technology for COVID-19

By The Science Advisory Board staff writers

June 5, 2020 -- AbbVie, Harbour BioMed, Utrecht University, and Erasmus Medical Center announced that they have entered into a collaboration to develop a novel antibody therapeutic agent to prevent and treat COVID-19.

The focus of the collaboration will be to advance the fully human neutralizing antibody, 47D11, that was discovered by Utrecht University, Erasmus Medical Center, and Harbour BioMed. The antibody discovery was reported in Nature Communications on May 4.

47D11 is a promising therapy based on the mechanism by which the antibody targets SARS-CoV-2. It blocks the conserved region of the spike protein and has been shown to block SARS-CoV-2 infection in cell culture studies.

Under the terms of the collaboration, AbbVie will support the other organizations through preclinical activities, while working to develop late-stage preclinical and clinical studies. AbbVie will receive an option to exclusively license the antibody from the three parties for therapeutic clinical development and commercialization worldwide.

Researchers investigate how a potent mAb blocks SARS-CoV-2
Based on previous research that explored therapies against SARS-CoV, a new report has identified a fully human monoclonal antibody (mAb) that prevents...

Copyright © 2020

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter